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Abstract
The use of vaccines including aluminum (Al)–based adjuvants is widespread among small ruminants and other animals. They
are associated with the appearance of transient injection site nodules corresponding to granulomas. This study aims to
characterize the morphology of these granulomas, to understand the role of the Al adjuvant in their genesis, and to
establish the presence of the metal in regional lymph nodes. A total of 84 male neutered lambs were selected and divided
into 3 treatment groups of 28 animals each: (1) vaccine (containing Al-based adjuvant), (2) adjuvant-only, and (3) control. A
total of 19 subcutaneous injections were performed in a time frame of 15 months. Granulomas and regional lymph nodes
were evaluated by clinicopathological means. All of the vaccine and 92.3% of the adjuvant-only lambs presented injection-
site granulomas; the granulomas were more numerous in the group administered the vaccine. Bacterial culture in granu-
lomas was always negative. Histologically, granulomas in the vaccine group presented a higher degree of severity. Al was
specifically identified by lumogallion staining in granulomas and lymph nodes. Al median content was significantly higher (P <
.001) in the lymph nodes of the vaccine group (82.65 mg/g) compared with both adjuvant-only (2.53 mg/g) and control
groups (0.96 mg/g). Scanning transmission electron microscopy demonstrated aggregates of Al within macrophages in
vaccine and adjuvant-only groups. In these two groups, Al-based adjuvants induce persistent, sterile, subcutaneous gran-
ulomas with macrophage-driven translocation of Al to regional lymph nodes. Local translocation of Al may induce further
accumulation in distant tissues and be related to the appearance of systemic signs.
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Sheep production in Spain very frequently involves vaccination
for prevention of a variety of diseases25 using vaccines that
include aluminum (Al)–based adjuvant. Vaccines are injected
throughout the life of the animals, and often a single sheep can
receive 2 to 4 vaccines per year or more depending on the
specific health problems of a certain flock or the implementa-
tion of compulsory vaccination campaigns against emerging
infections.7 The repetitive injection of Al-containing vaccines
in sheep has been related to a systemic, previously unreported
syndrome, the so-called ovine autoimmune/inflammatory syn-
drome induced by adjuvants (ovine ASIA syndrome). This was
widely observed following the compulsory bluetongue vacci-
nation campaign at the end of the past decade, which resulted in
severe deleterious effects on local sheep production.12,27,36 To
date, ovine ASIA syndrome is consistently observed in field
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conditions, and there is an urgent need to understand its patho-
genesis to control its effects.
Al salts are effective adjuvants that promote a robust
immune response against vaccine antigens and are considered
safe.1,26 Some studies indicate these compounds activate the
inflammasome pathway, induce a Th2 immune response, and
promote specific humoral immunity.1,9 In veterinary medicine,
granulomas associated with Al adjuvants are considered an
acceptable side effect,37 although the use of Al as adjuvant can
be related to a broad spectrum of local reactions at the injection
site, including chronic severe inflammation leading to sarco-
mas in cats.3,16,17 Sheep are considered prone to the develop-
ment of vaccine-associated granulomas37,40 and preclinical
safety studies for sheep vaccine development usually include
periodical in vivo evaluation of the reactions at the injection
site over a period of a few months.2,33
There are no reported histologic descriptions of the acute or
subacute inflammatory response to vaccines.15 Moreover, a
complete pathologic characterization of vaccine-induced gran-
ulomas in sheep, including location of Al within granulomas
and lymph nodes, has never been performed. This work aims to
characterize granulomas induced by vaccines that include an
Al-based adjuvant and to establish if Al is transported from the
injection site to the regional lymph node.
Materials and Methods
Study Design
The Ethical Committee of the University of Zaragoza approved
and licensed all experimental procedures (ref. PI15/14).
Requirements of the Spanish Policy for Animal Protection
(RED53/2013) and the European Union Directive 2010/63 on
the protection of experimental animals were always fulfilled.
The study was based on 4 flocks of 21, three-month-old,
neutered male lambs (N ¼ 84). Flock 1 was established at the
experimental farm of the University of Zaragoza and included
purebred Rasa Aragonesa lambs selected from a pedigree flock
of certified good health. This flock was always maintained
indoors, with optimal conditions of housing, management, and
diet. The animals that made up flocks 2 to 4 were selected from 3
commercial flocks representing different management
conditions and geographical areas (Suppl. Table S1). Flocks 2
to 4 were maintained within the original commercial flock for
the whole experiment. Each flock of 21 lambs was divided into 3
treatment groups (vaccine, adjuvant-only, and control; n ¼ 7
each). For the purpose of the present work, these 3 groups
included all animals under the same treatment (n ¼ 28 each).
Two animals from each treatment group died for unrelated rea-
sons during the course of the experiment; therefore, each group
consisted of 26 animals at the end of the experiment. The com-
plete study lasted 15 months, from February 2015 to April 2016.
Lambs underwent an accelerated vaccination schedule,
receiving, within an acceptable experimental time frame, an
Al load equivalent to 6 to 7 years in the field.25,27 Animals in
each treatment group received a total of 19 subcutaneous injec-
tions at 16 injection dates, as there were 3 days that required
double injections (Fig. 1). Periods between injections ranged
from 18 to 78 days (mean ¼ 30.2 + 16.0 days). All injections
were performed in the subcutaneous tissue of the area encom-
passing scapula and ribs. Sixteen injections were performed in
the right flank, and those 3 corresponding to double injection
dates were performed in the left flank. For the purpose of this
study, only the 16 injections in the right flank were considered.
The vaccine group was inoculated with commercial vac-
cines against major ovine diseases (Suppl. Table S2). The rec-
ommended period between vaccines and the application
procedure for each product was always fulfilled. The
adjuvant-only group was injected with Alhydrogel ®(CZ Veter-
inaria, Pontevedra, Spain), the Al-based adjuvant used in the
vaccine preparations. The concentration of Al for each inocu-
lum was calculated to be identical to that of the corresponding
vaccine by dilution with phosphate-buffered saline (PBS). The
Al content in the adjuvant and each vaccine was established by
inductively coupled plasma atomic emission spectrometry
(Suppl. Table S2). Vaccine and adjuvant-only groups received
a total of 81.29 mg of Al per animal. The control group was
inoculated with the same volume of PBS only. All animals
received the last injection 5 days prior to euthanasia.
In Vivo Studies
At each injection date, the same evaluator (J.A.) assessed by
palpation the severity of reaction to the injections. A range of
Figure 1. Vaccination schedule for this experiment. The number of days after the first injection is shown. Injection number is the sequential
number of a given injection. Vaccine number refers to the vaccine products as described in Suppl. Table S2.
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degree of severity was established (0–3): 0, no reaction, 1, 1
nodule-forming reaction smaller than 0.5 cm; 2, 1 nodule-
forming reaction bigger than 0.5 cm; 3, 1 nodule with central
liquefaction and/or fistulation or more than 1 palpable nodule-
forming reaction. This assessment was carried out up to and
including the 14th injection (Fig. 1).
Pathologic Characterization
A complete necropsy including a systematic sampling of all
tissues was performed, but for the purpose of this work, only
features recorded in the right flank or in the right prescapular
lymph node will be described. This sample collection proce-
dure guaranteed the required samples for the study (see below)
since the number of injections was higher in the right flank, and
helped in collecting the samples in a minimal time frame. The
subcutaneous tissue was exposed and the adipose panniculus
dissected. All grossly visible injection nodules were recovered
and their number recorded. The presence of central necrosis
within the nodules was also recorded. Depending on the num-
ber of nodules found in each animal, four categories were
established: 0, 1–2, 3–7, and 8 or more nodules.
For histopathologic purposes, only chronic, well-developed
nodules were considered, avoiding acute tissue reactions cor-
responding to the injections performed 5 days before euthana-
sia. Nodules were fixed and embedded in paraffin, but only 1
per animal was randomly selected for detailed histopathologic
studies. This procedure was based on the very homogeneous
histopathologic characteristics of nodules (see the Results
section). Samples were also obtained from the regional (right
prescapular) lymph node. In total, 47 injection-site nodules
(24 from the vaccine and 23 from the adjuvant-only animals),
26 control injection site areas, and 76 lymph nodes (26 from the
vaccine, 24 from adjuvant-only, and 26 from control animals)
were analyzed. Tissues were routinely processed and stained
with hematoxylin-eosin. The semiquantitative histopathologic
scoring system of the injection-site nodules and prescapular
lymph nodes is detailed in Supplemental Table S3 and Supple-
mental Table S4. Two authors (J.A. and L.L.) performed a
blind and individual microscopic evaluation of these para-
meters, reaching a final consensus.
Microbiology
A total of 40 animals (flocks 1 and 4) were studied by micro-
biological means: Twenty-six injection site nodules (13 from
the vaccine and 13 from the adjuvant-only groups), together
with 14 areas of injection from control animals, were submitted
for routine microbiologic studies. Each sample was studied by
direct Gram staining in smears and incubation of microbiologic
cultures in aerobic conditions (Columbia blood agar and
MacConkey agar; Oxoid, Basingstoke, Hampshire, UK; up to
48 hours at 37C) and anaerobic conditions (Columbia blood
agar, up to 5 days at 37C). Basic phenotypic bacterial identi-
fication was based on colony and cell (Gram stain) morphology
and by standard biochemical tests.
Aluminum In Situ Studies
The presence of Al in granulomas and lymph nodes was stud-
ied by fluorescence microscopy with lumogallion staining and
by electron microscopy. For fluorescence microscopy, 4 ran-
domly selected injection site nodules from animals in flock 1
(2 from the vaccine and 2 from the adjuvant-only groups)
were studied, along with two injection-site areas from control
lambs. Samples from the corresponding right prescapular
lymph nodes of the same six above-mentioned animals were
also analyzed. A protocol to identify Al in tissue sections
using lumogallion staining was followed.30,31 Briefly, 5-mm
tissue sections were dewaxed, rehydrated, and incubated with
a 1-mM solution of lumogallion (Tokyo Chemical Industry,
UK) prepared in 50 mM PIPES rinse solution. Serial control
sections were in PIPES rinse solution only. Slides were
washed 6 times with PIPES, rinsed in ultrapure water, and
mounted with an aqueous medium. Lumogallion and control
autofluorescence analyses were performed using a bandpass
excitation filter of 470 to 495 nm.
Eight randomly selected injection site nodules from flock 1
(4 from vaccine and 4 from adjuvant-only animals, including
those animals analyzed by fluorescence microscopy) were
submitted to scanning transmission electron microscopy
(STEM) and energy-dispersive X-ray spectroscopy (EDS).
Briefly, selected tissues were fixed in 2.5% glutaraldehyde
plus 2% paraformaldehyde (0.1 M PBS) washed in PBS, post-
fixed in 2% osmium, dehydrated in increasingly graded acet-
one, and embedded in araldite. Selected ultra-thin sections
were counterstained with 1% uranyl acetate and Reynold’s
lead citrate. STEM images were obtained in a Tecnai F30
microscope (FEI Company, Hillsboro, OR, USA) equipped
with an EDS detector. Al determinations by EDS were always
performed in intracytoplasmic aggregates, whereas determi-
nations in nuclei were used as internal negative controls. Al
particle size and Al aggregates area were measured using
STEM images: the length of Al particles was determined in
4 STEM images per animal at 68 000magnification by mea-
suring 10 particles per image (40 particles per animal), and the
area of Al aggregates was established in 4 STEM images per
animal at 8500 by measuring 5 well-delimited aggregates
per image (20 aggregates per animal). Large, dense eosino-
philic crystalloid bodies (made up of Al, see description
below; Suppl. Table S3) were not included in the calculation
of the area occupied by Al aggregates.
Aluminum Content in Lymph Nodes
Twelve lymph nodes (4 from each group, including the animals
analyzed by fluorescence microscopy, STEM, and EDS) were
analyzed by microwave digestion followed by transversely
heated graphite furnace atomic absorption spectroscopy (TH
GFAAS).19 Briefly, 3 replicate portions of 0.3 to 0.5 g from
each lymph node were dried in a 37C incubator until reaching
a constant weight. They were then digested in a microwave
(MARS Xpress CEM Microwave Technology Ltd.) in a
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mixture of 1 mL 15.8 M HNO3 and 1 mL of 30% w/v H2O2.
Upon cooling, each digest was diluted to 5 mL with ultrapure
water, and total Al was measured using an atomic absorption
spectrometer with a transversely heated graphite atomizer,
longitudinal Zeeman-effect background corrector, and an
AS-800 autosampler with WinLab32 software (PerkinElmer,
Buckinghamshire UK). The Zeeman background corrected
peak area of the atomic absorption signal was used for deter-
minations. Results were expressed as micrograms of Al per
gram of tissue dry weight. Each determination was the
Figures 2–7. Injection site granulomas, subcutaneous tissue of the right flank (fat has been removed), lambs injected subcutaneously with
vaccine or adjuvant-only. Figure 2. Vaccine group. Multiple well-defined granulomas are observed. Figure 3. Vaccine group. Thirteen
subcutaneous granulomas isolated from a single animal. Nodules used for microbiology and electron microscopy are not present. Figure 4.
Vaccine group. Well-defined, round, and prominent granuloma. Figure 5. Adjuvant-only group. Ill-defined, flat, and inconspicuous granuloma.
Figures 6–7. Cut section of granulomas. Figure 6. Vaccine group. Massive central sterile caseous necrosis. Figure 7. Adjuvant-only group.
Homogeneous and solid aspect, with no apparent necrosis.
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arithmetic mean of 3 injections, with a relative standard devia-
tion of 10%.
Statistical Analysis
Qualitative variables, as groups of treatment and histopatholo-
gic features, were described using absolute and relative
frequencies. Assessment of the associations between 2 qualita-
tive variables was carried out using Pearson’s chi-square test
(or, alternatively, likelihood ratio for n  m tables or Fisher’s
exact test for 2  2 tables).5
Shapiro-Wilk test was used to check if the data of the quan-
titative variables (severity of the in vivo reactions, Al particle
length/aggregates, and Al content) followed a normal distribu-
tion. As all of them were not normal, they were described using
median and interquartile range (IQR) and graphically repre-
sented using box and whiskers plots. Association of a nonnor-
mal quantitative variable with a qualitative variable with 2
categories was assessed by Mann-Whitney U test (ie, compar-
ison of the severity of the in vivo reactions, Al particle length,
and Al aggregates area between the vaccine and adjuvant-only
groups). Association of a nonnormal quantitative variable with
a qualitative variable with 3 or more categories was assessed by
Kruskal-Wallis test followed by a post hoc Dunn’s test (ie,
comparisons of the content in Al in the regional lymph nodes
among the 3 groups).5
Data were analyzed using IBM SPSS 19.0 for Windows




In vivo assessment of local reactions is shown in Suppl. Fig. S1.
Injection-site nodules were palpated only in the vaccine and
adjuvant-only groups. Local reactions in the vaccine group
showed a significantly higher (P < .001) degree of severity
(cumulative median¼ 0.79, IQR¼ 0.59–1.04) when compared
with adjuvant-only animals (cumulative median ¼ 0.36,
IQR ¼ 0.21–0.50). Peaks of severity were observed in both
groups in parallel and were associated with a high Al dose in
the immediately previous injection. In general, only 1 nodule
was palpated per animal, and most of the liquefactive and
fistula-forming nodules were observed in the vaccine group
(data not shown).
Gross and Histopathology
Inspection of the subcutaneous tissue after the removal of the
adipose panniculus revealed the presence of nodules, although
only in the vaccine and adjuvant-only groups (Fig. 2). All (26/
26; 100%) lambs of the vaccine group and most (24/26, 92.3%)
of the adjuvant-only animals presented nodules, whereas the
control group (0/26; 0%) did not (Table 1). More than half of
the adjuvant-only lambs showed 1 or 2 nodules in total,
whereas more than 75% of the vaccine animals exhibited 8
nodules or more; the minimum number of nodules recovered
in vaccine animals was 3 (Table 1). Remarkably, 7 vaccine
lambs (7/26, 26.9%) showed between 13 and 16 nodules in the
right flank (Fig. 3). Vaccine-induced nodules were round and
conspicuous (Fig. 4), whereas adjuvant-only–induced nodules
tended to be plaque-like or at least not as round (Fig. 5). In both
groups, nodule size was generally within a range of 0.5 and 2
cm. However, especially in the adjuvant-only group, some
nodules were difficult to locate because of their small size
(sometimes less than 2 mm). Central caseous necrosis of
nodules was grossly observed in 84.6% and in 13.6% of the
vaccine and adjuvant-only lambs, respectively (Figs. 6, 7).
The basic histologic features of the injection site nodules and
regional lymph nodes were comparable within and between the 2
treated groups, varying only in their intensities (Table 2), while
no control animals presented with injection site reactions. In the
2 treated groups, nodules consisted of well-demarcated granulo-
mas mostly composed of voluminous, activated macrophages
showing a vacuolated to coarsely granulated cytoplasm
(Figs. 8, 9). Multinucleated giant cells, either Langhans or
foreign-body type, were observed significantly more often in
granulomas from vaccine animals (P ¼ .010; Fig. 8, inset).
Lymphocyte aggregates were observed at the periphery of gran-
ulomas in half of the animals of both groups. Significantly
higher degrees of central necrosis (P ¼ .021; Fig. 8) and miner-
alization (P ¼ .001) were observed in granulomas of vaccinated
lambs, together with a significant presence of neutrophils
(P ¼ .009). In both groups, scattered within the granulomas,
well-defined, straight-bordered, intra- and extracellular, round
to elongated (cigarette-shaped) eosinophilic crystalloid bodies
of approximately 100–200 mm were observed. These bodies
were significantly overrepresented in adjuvant-only granulomas
(P < .001; Fig. 9). The prescapular lymph nodes of vaccine and
adjuvant-only lambs showed significant cortical hyperplasia
(P < .001) and significant presence of clusters of voluminous,
foamy to granulated macrophages (P < .001; Fig. 10).
Using lumogallion staining, a granular, intense intracytoplas-
mic orange fluorescence was observed in macrophages from
granulomas and lymph nodes from both vaccine and adjuvant-
only groups (Fig. 11). Remarkably, the eosinophilic crystalloid
bodies observed with hematoxylin and eosin showed the most
intense orange fluorescence (Fig. 12). Fluorescence of similar
characteristics was not observed in tissues from control lambs.
Table 1. Number (%) of Granulomas Collected Postmortem in
Lambs Injected With Phosphate-Buffered Saline (Control), Adjuvant-
Only or Vaccines (n ¼ 26 Animals per Group).a
No. of Granulomas
Group 0 1–2 3–7 8
Control 26 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Adjuvant 2 (7.7) 14 (53.9) 7 (26.9) 3 (11.5)
Vaccine 0 (0.0) 0 (0.0) 6 (23.1) 20 (76.9)
a Association was assessed using likelihood ratio (P < .001).
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Table 2. Histologic Lesions in Subcutaneous Granulomas and Lymph Nodes in Lambs Injected Subcutaneously With Phosphate-Buffered Saline





(n ¼ 24) P
Voluminous macrophages 0
NA
0 (0) 0 (0)
.232LR
1 0 (0) 1 (4.2)
2 5 (21.7) 2 (8.3)
3 18 (78.3) 21 (87.5)
Multinucleated giant cells þ
NA
15 (65.2) 23 (95.8)
.010F– 8 (34.8) 1 (4.2)
Lymphocytes þ
NA
12 (52.2) 13 (54.2)
>.999F– 11 (47.8) 11 (45.8)
Tertiary lymphoid tissue þ
NA
2 (8.7) 3 (12.5)
>.999F– 21 (91.3) 21 (87.5)
Neutrophils þ
NA
7 (30.4) 17 (70.8)
.009F– 16 (69.6) 7 (29.2)
Necrosis 0
NA
14 (60.9) 7 (29.2)
.021LR
1 4 (17.4) 2 (8.3)
2 2 (8.7) 2 (8.3)
3 3 (13.0) 13 (54.2)
Mineralization 0
NA
21 (91.3) 11 (45.8)
.001LR
1 2 (8.7) 3 (12.5)
2 0 (0) 5 (20.8)
3 0 (0) 5 (20.8)
External fibrosis (capsule) þ
NA
20 (87.0) 24 (100)
.109F– 3 (13.0) 0 (0)
Internal fibrosis þ
NA
21 (91.3) 17 (70.8)
.137F– 2 (8.7) 7 (29.2)
Internal hemorrhages þ
NA
4 (17.4) 5 (20.8)
>.999F– 19 (82.6) 19 (79.2)
External hemorrhages þ
NA
1 (4.3) 2 (8.3)
>.999F– 22 (95.7) 22 (91.7)
Internal blood vessels þ
NA
23 (100) 24 (100)
—– 0 (0) 0 (0)
Eosinophilic crystalloid bodies 0 NA 4 (17.4) 19 (79.2) <.001LR
1 4 (17.4) 2 (8.3)
2 8 (34.8) 2 (8.3)







(n ¼ 26) P
Cortical hyperplasiab 0 1 (3.8) 0 (0) 0 (0)
<.001LR
1 9 (34.6) 2 (8.3) 1 (3.8)
2 15 (57.7) 10 (41.7) 10 (38.5)
3 1 (3.8) 12 (50.0) 15 (57.7)
Prominent germinal centers 0 0 (0) 0 (0) 0 (0)
.060w
21 9 (34.6) 2 (8.3) 4 (15.4)
2 12 (46.2) 11 (45.8) 9 (34.6)
3 5 (19.2) 11 (45.8) 13 (50.0)
Aggregates of voluminous macrophagesb þ 3 (11.5) 22 (91.7) 22 (84.6)
<.001w
2
– 23 (88.5) 2 (8.3) 4 (15.4)
Abbreviations: NA, not applicable; LR, likelihood ratio; F, Fisher’s exact test; w2, Pearson’s chi-square test; þ, presence; –, absence.
a The data show the number (and percentage) of animals with each lesion.
b Significant difference refers to comparing vaccine/adjuvant-only groups with control group.
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Electron Microscopy Studies
Macrophages within granulomas contained needle-shaped,
electron-dense material (Fig. 13) that formed multiple intracy-
toplasmic aggregates, often surrounded by a subcellular mem-
brane (phagolysosome; Figs. 14, 15). This membrane showed
occasional areas of discontinuity and loss, leading to the pres-
ence of free intracytoplasmic spiculated material. The eosino-
philic, lumogallion-positive crystalloid bodies showed a dense
and uniform aggregation of the same spiculated material (Fig.
16). Independently of the presentation and location, this
needle-shaped material was identified as Al by EDS, and other
frequently identified elements were carbon, oxygen, lead, copper,
and osmium (Fig. 17). EDS measurements performed in
nuclei were always negative for Al. Al particles in granulomas
were significantly longer (P < .001) in the vaccine group
(median ¼ 121.24 nm, IQR ¼ 98.30–170.60) than particles in
the adjuvant-only group (median ¼ 69.47 nm, IQR ¼ 53.53–
87.62; Fig. 18). The area of aggregates was similar in both groups
(vaccine: median¼ 1.71 mm2, IQR ¼ 0.84–3.10; adjuvant-only:
median¼ 1.80 mm2, IQR¼ 1.19–2.80; Fig. 19). Finally, macro-
phages in both groups showed 1 or more of the following degen-
erative changes: swollen rough endoplasmic reticulum with
prominent ribosomes, swollen mitochondria with disorganization
of cristae, intracytoplasmic myelin figures, nuclear membrane
blebs, and indentations and margination of heterochromatin.
Microbiology
All 26 granulomas and the 14 injection site areas from control
lambs were negative for bacteriological cultures, and no bac-
terial forms were observed with Gram staining.
Figures 8–9. Injection site granulomas. Lambs injected subcutaneously with vaccine or adjuvant-only. Figure 8. Vaccine group. Dense
aggregates of epithelioid macrophages and multinucleated giant cells and a regionally extensive area of necrosis (asterisk). Inset: multinucleated
giant cells contain foamy cytoplasm. Hematoxylin and eosin (HE). Figure 9. Adjuvant-only group. Aggregates of epithelioid macrophages with
few multinucleated giant cells intermingled with intra- and extracellular eosinophilic crystalloid bodies. Inset: Several eosinophilic crystalloid
bodies in close relationship with multinucleated giant cells. HE. Figures 10–11. Right prescapular lymph nodes. Figure 10. Adjuvant-only
group. Coalescing aggregates of macrophages. HE. Figure 11. Vaccine group. Aggregates of macrophages showing aluminum (Al)–positive
fluorescence. Lumogallion. Figure 12. Injection site granuloma, adjuvant-only group. Macrophages showing intracytoplasmic Al-positive orange
fluorescence with a granular pattern. Eosinophilic crystalloid bodies show strong positive fluorescence. Lumogallion. Inset: Absence of auto-
fluorescence in an unstained sequential section.
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Aluminum Content in Lymph Nodes
The content of Al in lymph nodes is detailed in Table 3. The
vaccine group contained significantly higher values than the
other 2 groups (P < .001), and the content of Al in the adjuvant-
only animals was also significantly higher than in the control
(P < .001).
Discussion
This is the first comprehensive description of the morphology of
persistent granulomas in sheep following injection with either
vaccines containing Al-based adjuvants or the Al-based adjuvant
alone. Al was unequivocally identified by different methods both
in granulomas and lymph nodes, with higher lesion severity in
granulomas from vaccinated lambs. The ultrastructure of the
granulomas varied according to whether Al was administered
as a vaccine preparation or simply as an adjuvant. The transloca-
tion of Al from the injection site to the lymph node was demon-
strated for the first time in a large animal model.
This experiment was planned to study the lesions caused by
the administration of Al adjuvant-containing products, indepen-
dent of the identification of individual injections, the exact age
of the granuloma, or the role of specific vaccine antigens, as
evaluated in other studies.39 Our results showed that granuloma
was the only type of local reaction produced by these injections,
differing only in shape, persistency, and histopathologic aspects.
Lambs in this experiment were sourced from 4 different
flocks. However, in vivo measurements and observations of
gross and microscopic changes were similar, irrespective of
flock, breed, or management conditions. Therefore, these
observations are combined as 3 experimental groups.
Figures 13–17. Injection site granulomas, lambs injected with vaccine or adjuvant. Scanning transmission electron microscopy and energy-
dispersive X-ray spectroscopy (EDS). White circles in the electron micrographs show areas of EDS measurements. Figure 13. Vaccine group.
Long and prominent electron-dense spiculated particles, identified as aluminum (Al). Bar ¼ 100 nm. Figure 14. Vaccine group. Macrophage
containing cytoplasmic vesicles (arrows) containing the spiculated electron-dense material identified as Al. Nuclear condensation and periph-
eralization of heterochromatin. N: nucleus. Bar ¼ 1 mm. Figure 15. Adjuvant-only group. Aggregates of Al enclosed in different-sized
phagolysosomes (arrows) and nuclear elongation. N: nucleus. Bar ¼ 1 mm. Figure 16. Adjuvant-only group. Large and straight-bordered
aggregate of densely packed material, which corresponds to the eosinophilic crystalloid bodies observed by hematoxylin-eosin. These aggre-
gates show electron-dense borders. N: nucleus. Bar ¼ 1 mm. Inset: Higher magnification of the aggregate border. Bar ¼ 200 nm. Figure 17.
Representative EDS graph. The spiculated electron-dense material and the crystalloid bodies (indicated in white circles in Figs. 14, 15, and 16)
were always identified as Al (peak indicated by a black circle).
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Gross pathology data demonstrated that injection site gran-
ulomas were much more numerous than was noticed by in vivo
examination. In sheep, these reactions are reported to disappear
with time, although it is not known exactly how long this
takes.33 The gross data underline that the development of gran-
ulomas in both treated groups was very common and was a
universal fact in the vaccine animals. More than 75% of vac-
cine animals demonstrated at least 8 granulomas, indicating
more frequent development or persistence of granulomas
induced by vaccines. Assuming that each granuloma corre-
sponded to a different single injection, the postmortem detec-
tion of granulomas in all injection sites would indicate that they
may persist for at least 15 months, the duration of the current
experiment. This persistence might reflect a low capacity, per-
haps genetic, for clearing Al from the injection site in certain
lambs, as has also been postulated in humans with specific
human leukocyte antigen polymorphisms.14 Granulomas
induced in adjuvant-only animals showed a lower persistency,
which might indicate a quicker clearance of Al, perhaps due to
a less severe immune reaction from the lack of antigen and/or
different Al particle conformation.
Histologically, the reactions observed were interpreted as
immune-mediated granulomas (ie, they are induced by persis-
tent immunostimulating agents).24 In the vaccine group, there
were more frequent and extensive necrotic centers, which
might be due to the presence of antigens, different Al particle
conformations, or a combination of both. It is known that Al
particle size can increase in the presence of antigens,35 and
indeed our results point to a higher particle size in vaccine
granulomas. Al particles have been linked to phagolysosome
membrane disruption and release of Al into the cytoplasm,
leading to cell death by activating the cathepsin-mediated
necrosis pathway.20 Indeed, a relationship between particle size
and the immunostimulation capability of different adjuvants
has been postulated.32,41 Therefore, a different particle confor-
mation due to the interaction with antigen may induce an
increased immune stimulation, leading to a higher degree of
tissue necrosis in vaccine granulomas. More accurate meth-
ods21,35 should be employed to determine real particle size,
as our measurements are only 2-dimensional estimations of
particle length for comparison purposes. We describe for the
first time large dense Al aggregates in the form of pale crystal-
loid eosinophilic bodies with straight borders within the gran-
ulomas, the number of which was significantly increased in the
adjuvant-only group. The reason for formation of these crystal-
loid bodies remains obscure, and further research is needed to
clarify their role in the genesis of the granulomas and subse-
quent interactions with the surrounding tissues.
Lumogallion demonstrated excellent performance in granu-
lomas and lymph nodes, giving an Al-selective orange fluores-
cence30,31 that is easier to interpret than other stains.13 This
technique has recently been used to reliably identify Al in
tissues from rats fed an Al-containing diet.28 EDS has been
previously used to determine the presence of Al in postvaccine
granulomas in pigs38 and humans.22 The presence of other
elements in EDS determinations are explained by the technical
processing of the samples: lead and osmium are part of the
staining, and copper is in the grid.38 TH GFAAS has been used
to determine Al content in human29 and animal tissues.4,28 In
our study, this technique demonstrated a significant increase of
Al in lymph nodes of vaccine lambs when compared with both
adjuvant-only and control animals. Quantitative analyses using
TH GFAAS and qualitative imaging using lumogallion demon-
strate for the first time in a large animal model that Al is carried
in macrophages from the injection site to lymph nodes. In fact,
Figure 18. Length of the aluminum (Al) particles in granuloma macro-
phages. Boxes represent the interquartile range, and horizontal lines
inside the boxes represent the median values. Whisker bars represent
the variability of the data outside the interquartile range. Points and
squares represent the outlier measurements in each group. Vaccine
granulomas have significantly longer aluminum particles than adjuvant-
only granulomas. *P < .001, Mann-Whitney U test.
Figure 19. Area of aluminum (Al) aggregates in granuloma macro-
phages. Boxes represent the interquartile range, and horizontal lines
inside the boxes represent the median values. Whisker bars represent
the variability of the data outside the interquartile range. Points and
squares represent the outlier measurements in each group. Vaccine
and adjuvant-only granulomas show a similar aggregate area. *P < NS,
Mann-Whitney U test.
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egress of mycobacteria-infected macrophages from granulo-
mas is a well-described mechanism,6 and translocation of
metals to lymph nodes has recently been reported in a case
of a dog with hip-implant–associated metallosis8 and also in
humans with subcutaneous tattoos that carry a variety of
metals, including Al.34 The Al translocation observed in this
work might suggest a systemic distribution throughout the
body, as demonstrated in mice23 or rabbits.11 In our animals,
Al-containing macrophages tended to form aggregates in the
lymph nodes, as has been similarly observed in mice.18,23 Some
control lambs showed rare, similar but smaller macrophage
aggregates, negative to lumogallion staining, in the draining
lymph node (Table 2) that might simply indicate the drai-
nage of other, nonrelated lipidic phagocytic debris to the
lymph node.10
This experiment was part of a comprehensive study to
improve understanding of the ovine ASIA syndrome, and it has
been successful in reproducing some, but not all, of its most
remarkable changes. Vaccine and adjuvant-only groups
demonstrated significant changes in the interindividual and
intragroup interaction patterns (ie, increase in wool biting and
restlessness) as the cumulative number of injections increased.
These findings coincide with previous observations on the
ovine ASIA syndrome.27 Treatment groups also showed higher
levels of stress biomarkers, and the clinicopathological picture
as a whole showed few significant differences between these
groups. These results will be published in detail elsewhere.
Conclusion
In sheep, persistent subcutaneous granuloma formation is a
universal reaction to the injection of Al either in commercial
vaccines or simply as Al-based adjuvants. We show that Al is
subsequently transported from the injection site to the lymph
nodes. This transport was far more pronounced in the commer-
cial vaccine preparations, which suggests that the animal han-
dles Al differently depending upon its presentation at injection
sites. Further research is needed to study the putative role of
this tissue reaction in the development of the previously
described ovine ASIA syndrome.
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